Skip to search formSkip to main contentSkip to account menu

BMS-650032

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

asunaprevir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A highly sensitive and selective LC-MS/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies.
2013
2013
HCV NS5A Inhibitors in Development
  • A. Lok
  • 2013
  • Corpus ID: 196384714
Review
2013
Review
2013
HCV NS5A inhibitors in development.
2012
2012
Single-and Multiple-Ascending-Dose Studies of the NS 3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C
Claudio Pasquinelli, Fiona McPhee, Timothy Eley, Criselda Villegas, Katrina Sandy, Pamela Sheridan, Anna Persson, Shu-Pang Huang… 
2011
2011
63 CHARACTERIZATION OF VIROLOGIC ESCAPE IN HCV GENOTYPE 1 NULL RESPONDERS RECEIVING A COMBINATION OF THE NS3 PROTEASE INHIBITOR BMS-650032 AND NS5A INHIBITOR BMS-790052
2011
2011
1223 NO EARLY VIROLOGIC BREAKTHROUGH OBSERVED WITH THE HCV NS3 PROTEASE INHIBITOR BMS-650032 IN MULTIPLE DOSE MONOTHERAPY STUDIES AND PHASE 2A COMBINATION STUDIES WITH PEGIFNα/RBV
Review
2011
Review
2011
Emerging therapeutic options in hepatitis C virus infection.
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is pegylated interferon alfa in… 
2011
2011
THE HEPATITIS C TREATMENT PIPELINE REPORT
BMS-650032 • BOCEPREVIR • CTS-1027 • DANOPREVIR • GS 9256 GS 9451 • IDX 320 • MK-5172 • TELAPREVIR • TMC435350 • VANIPREVIR VX… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)